Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance

• Published in: International journal of clinical oncology 2023-01, Vol.28 (1), p.130-138
• Main Authors: Watanabe, Jun, Terazawa, Tetsuji, Yamane, Shiho, Kazama, Hirotaka, Uetake, Hiroyuki, Yoshino, Takayuki
• Format: Article
• Language: English
• Subjects: 5-Fluorouracil; Appetite loss; Cancer Research; Colorectal cancer; Colorectal carcinoma; Diarrhea; Disease control; Gastrointestinal tract; Irinotecan; Medicine; Medicine & Public Health; Metastases; Metastasis; Neutropenia; Oncology; Original; Original Article; Patients; Proteinuria; Safety; Solid tumors; Surgical Oncology; Surveillance
• ISSN: 1341-9625; 1437-7772
• DOI: 10.1007/s10147-022-02259-w

Background Safety and effectiveness of aflibercept with 5‐fluorouracil/levofolinate/irinotecan have not been reported in Japanese patients with metastatic colorectal cancer (mCRC) in a real-world clinical setting. Methods This post-marketing surveillance enrolled patients with un-resectable advanced or recurrent mCRC who were prescribed aflibercept from December 2017 to June 2019 in Japan. Data, collected up to 1 year from starting treatment, included patient background, safety, and effectiveness assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or physician’s evaluation. Results Of 261 patients registered from 64 centers, 235 [53.2% male with a median age of 67 years (range 28–84)] received treatment and were included in the safety analysis. Aflibercept was received at 1st, 2nd, and ≥ 3rd line in 1.3%, 48.1%, and 50.2% of patients, respectively. Median number of treatment cycles was 6 (range 1–22) and relative dose intensity was 75.4% (range 14.3–101.8%). Adverse events (all grades) were reported in 88.5% of patients, including neutropenia (34.5%), proteinuria (24.7%), hypertension (17.0%), diarrhea (17.0%), and decreased appetite (15.3%). Three treatment-related deaths occurred by perforation of the digestive tract, pneumonia and gastrointestinal bleeding, and sudden death. The effectiveness analysis included 198 patients. Overall response rate was 6.1% (1st line, 0%; 2nd line, 10.1%; ≥ 3rd line, 2.1%) and disease control rate was 47.5% (1st line, 100%; 2nd line, 58.6%; ≥ 3rd line, 34.4%). Conclusion No new risks of aflibercept were identified in real clinical practice. Effectiveness in patients at the 2nd line was consistent with previous reports.